ArticleGenome medicine2025
Transcriptome-wide association study revealed novel causal genes of renal-biopsy proven diabetic nephropathy.
Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile genome-wide association studies (GWAS) have shown that genetic variants are linked to diabetic nephropathy (DN), the precise gene responsible for influencing risk remains largely unidentified, and the issue of missing heritability persists. This study seeks to identify new pathogenic genes using transcriptome-wide association study (TWAS) analysis in a cohort with renal biopsy-proven DN.
methodsA TWAS was conducted to investigate potential DN risk genes whose expression mediates the genotype effect on the phenotype. Gene expression levels were entered into our existing DN GWAS cohort including 2,279 renal biopsy-proven DN and 3,762 type 2 diabetes more than 10 years without any microvascular complications by using GEMMA software. The TWAS P-values were calculated using logistic regression models. Public data from ENCODE and GEO were obtained to annotate the function of genes and variants. Pathway enrichment analysis was performed with co-expressed genes. The role of GYS1 in DN was determined using Gys1-antisense oligonucleotide (ASO) in db/db mice.
resultsThe expression levels of 4,703 cis-heritable genes were analyzed from our renal biopsy-proven DN GWAS dataset. The TWAS results identified 17 genes (9 glomerular-only, 5 tubulointerstitial-only, and 3 shared) that were statistically significantly associated with DN susceptibility in both glomerular and tubulointerstitial regions. Notably, GYS1 and FOXJ2 emerged as novel findings. Furthermore, a gene prioritization strategy was developed, involving gene differential expression validation, clinical and pathological indicator correlation, and functional variant exploration. This approach identified GYS1 as the top causal gene. Risk variants (rs116573491 and rs111518556) of GYS1 were both discovered to increase GYS1 expression in vitro. GYS1 was found to be enriched in glomerular mesangial cells and was elevated in DN compared to healthy controls. Additionally, the level of GYS1 in glomeruli was inversely correlated with estimated GFR (eGFR) and positively correlated with 24-h proteinuria in DN patients. Gys1-ASO therapy halted the progression and development of DKD in db/db mice by reducing Gys1 expression.
conclusionsThis biopsy-based TWAS identifies 17 DN susceptibility genes and prioritized GYS1 as a probable driver of DN, links genetic risk to mesangial dysfunction, and demonstrates that Gys1 suppression mitigates disease progression, supporting GYS1 as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.